Do RANKL inhibitors (denosumab) affect inflammation and immunity
Do RANKL inhibitors (denosumab) affect inflammation and immunity
About this item
Full title
Author / Creator
Publisher
London: London : Springer-Verlag
Journal title
Language
English
Formats
Publication information
Publisher
London: London : Springer-Verlag
Subjects
More information
Scope and Contents
Contents
Receptor activator of nuclear factor kappa B ligand (RANKL) and its natural antagonist, osteoprotegerin (OPG), are, respectively, an indispensable factor and a potent inhibitor for osteoclast differentiation, activity, and survival. The development of a human monoclonal antibody to RANKL, denosumab, constitutes a novel approach to prevent fragility...
Alternative Titles
Full title
Do RANKL inhibitors (denosumab) affect inflammation and immunity
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_954609606
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_954609606
Other Identifiers
ISSN
0937-941X
E-ISSN
1433-2965
DOI
10.1007/s00198-010-1326-y
